A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

Dirk Rades; Jaspar Witteler; Steven E Schild; Peter Trillenberg; Matteo M Bonsanto; Jan Leppert

doi:10.21873/anticanres.14786

A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

Dirk Rades, Jaspar Witteler, Steven E Schild, Peter Trillenberg, Matteo M Bonsanto, Jan Leppert

Mayo Clinic Scottsdale, AZ

Abstract

BACKGROUND/AIM: In a previous study investigating radiotherapy for newly diagnosed glioblastoma multiforme (GBM), significant or almost significant associations with survival were found for performance status, upfront resection, O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation and unifocal GBM. This study aimed to create a survival score based on these factors.

PATIENTS AND METHODS: Most of the 81 patients included received resection of GBM followed by radiochemotherapy (59.4 Gy/33 or 60 Gy/30 fractions). The previously identified predictors of survival were re-evaluated. Factors significantly associated with survival were used for the score.

RESULTS: All factors were significantly associated with survival. For each factor, 0 points (less favorable survival) or 1 point (more favorable survival) were assigned and added for each patient. Three groups were designed, 0-1 (n=10), 2 (n=21) and 3-4 points (n=50); 12-month survival rates were 0%, 38% and 78% (p<0.001).

CONCLUSION: A new survival score was created for patients requiring radiotherapy for GBM that can improve treatment personalization.

Original language	English
Journal	Anticancer Research
Volume	41
Issue number	1
Pages (from-to)	379-384
Number of pages	6
ISSN	0250-7005
DOIs	https://doi.org/10.21873/anticanres.14786
Publication status	Published - 01.01.2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.14786

Cite this

@article{678706de215a4a55a7cd415b2a2f3123,

title = "A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme",

abstract = "BACKGROUND/AIM: In a previous study investigating radiotherapy for newly diagnosed glioblastoma multiforme (GBM), significant or almost significant associations with survival were found for performance status, upfront resection, O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation and unifocal GBM. This study aimed to create a survival score based on these factors.PATIENTS AND METHODS: Most of the 81 patients included received resection of GBM followed by radiochemotherapy (59.4 Gy/33 or 60 Gy/30 fractions). The previously identified predictors of survival were re-evaluated. Factors significantly associated with survival were used for the score.RESULTS: All factors were significantly associated with survival. For each factor, 0 points (less favorable survival) or 1 point (more favorable survival) were assigned and added for each patient. Three groups were designed, 0-1 (n=10), 2 (n=21) and 3-4 points (n=50); 12-month survival rates were 0%, 38% and 78% (p<0.001).CONCLUSION: A new survival score was created for patients requiring radiotherapy for GBM that can improve treatment personalization.",

author = "Dirk Rades and Jaspar Witteler and Schild, {Steven E} and Peter Trillenberg and Bonsanto, {Matteo M} and Jan Leppert",

year = "2021",

month = jan,

day = "1",

doi = "10.21873/anticanres.14786",

language = "English",

volume = "41",

pages = "379--384",

journal = "Anticancer Research",

issn = "0250-7005",

number = "1",

}

TY - JOUR

T1 - A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

AU - Rades, Dirk

AU - Witteler, Jaspar

AU - Schild, Steven E

AU - Trillenberg, Peter

AU - Bonsanto, Matteo M

AU - Leppert, Jan

PY - 2021/1/1

Y1 - 2021/1/1

N2 - BACKGROUND/AIM: In a previous study investigating radiotherapy for newly diagnosed glioblastoma multiforme (GBM), significant or almost significant associations with survival were found for performance status, upfront resection, O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation and unifocal GBM. This study aimed to create a survival score based on these factors.PATIENTS AND METHODS: Most of the 81 patients included received resection of GBM followed by radiochemotherapy (59.4 Gy/33 or 60 Gy/30 fractions). The previously identified predictors of survival were re-evaluated. Factors significantly associated with survival were used for the score.RESULTS: All factors were significantly associated with survival. For each factor, 0 points (less favorable survival) or 1 point (more favorable survival) were assigned and added for each patient. Three groups were designed, 0-1 (n=10), 2 (n=21) and 3-4 points (n=50); 12-month survival rates were 0%, 38% and 78% (p<0.001).CONCLUSION: A new survival score was created for patients requiring radiotherapy for GBM that can improve treatment personalization.

AB - BACKGROUND/AIM: In a previous study investigating radiotherapy for newly diagnosed glioblastoma multiforme (GBM), significant or almost significant associations with survival were found for performance status, upfront resection, O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation and unifocal GBM. This study aimed to create a survival score based on these factors.PATIENTS AND METHODS: Most of the 81 patients included received resection of GBM followed by radiochemotherapy (59.4 Gy/33 or 60 Gy/30 fractions). The previously identified predictors of survival were re-evaluated. Factors significantly associated with survival were used for the score.RESULTS: All factors were significantly associated with survival. For each factor, 0 points (less favorable survival) or 1 point (more favorable survival) were assigned and added for each patient. Three groups were designed, 0-1 (n=10), 2 (n=21) and 3-4 points (n=50); 12-month survival rates were 0%, 38% and 78% (p<0.001).CONCLUSION: A new survival score was created for patients requiring radiotherapy for GBM that can improve treatment personalization.

UR - http://www.scopus.com/inward/record.url?scp=85099680618&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/19cdf15b-736a-30ef-8eb3-8346c750fce3/

U2 - 10.21873/anticanres.14786

DO - 10.21873/anticanres.14786

M3 - Journal articles

C2 - 33419834

SN - 0250-7005

VL - 41

SP - 379

EP - 384

JO - Anticancer Research

JF - Anticancer Research

IS - 1

ER -

A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this